Kurse werden geladen...
Prognose
Kaufen | 8 |
Halten | 2 |
Verkaufen | 0 |
Scoring-Modelle
Dividenden-Strategie | 0 / 15 |
HGI-Strategie | 3 / 18 |
Levermann-Strategie | -5 / 13 |
News
Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy
SAN DIEGO and CALGARY, Alberta , June 30, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Andrew Aromando as Chief Business Officer. Mr. Aromando most recently served as Chief Operating Officer at Ambrx Biopharma, where his contributions were instrumental in the $2 billion acquisition of the San Diego-based biotech by Johnson & Johnson.» Mehr auf prnewswire.com
Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs
SAN DIEGO and CALGARY, AB , June 11, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Jared Kelly as Chief Executive Officer and a member of its Board of Directors. Mr. Kelly is a successful biotech executive who has proven expertise in transformative deals and corporate strategy.» Mehr auf prnewswire.com
Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities
Pelareorep initiates a pro-inflammatory tumor microenvironment (TME) and induces innate and adaptive immune responses New analyses confirm that pelareorep primes the TME to allow circulating tumor-infiltrating lymphocytes (TILs) in the blood to attack tumors Pre-existing TIL clones in plasma may correlate positively with tumor shrinkage in pancreatic cancer SAN DIEGO and CALGARY, AB , May 23, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced new data from the Phase I/II GOBLET clinical trial in a poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation highlights pelareorep's mechanism of action in pancreatic ductal adenocarcinoma (PDAC), offering new insights into how this immunotherapy stimulates multiple arms of the immune system and primes tumors for treatment.» Mehr auf prnewswire.com
Unternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 0,00 | - |
Bruttoeinkommen | 0,00 | 100,00% |
Nettoeinkommen | −4,30 Mio | 9,08% |
EBITDA | −4,43 Mio | 24,80% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 56,42 Mio€ |
Anzahl Aktien | 88,82 Mio |
52 Wochen-Hoch/Tief | 1,30€ - 0,28€ |
Dividenden | Nein |
Beta | 1,19 |
KGV (PE Ratio) | −2,75 |
KGWV (PEG Ratio) | −1,15 |
KBV (PB Ratio) | 13,34 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
Oncolytics Biotech Inc. ist ein biopharmazeutisches Unternehmen im Entwicklungsstadium, das sich auf die Entdeckung und Entwicklung von pharmazeutischen Produkten für die Behandlung von Krebs spezialisiert hat. Sein Hauptprodukt ist Pelareorep, ein intravenös verabreichtes Immuntherapeutikum zur Behandlung von soliden Tumoren und hämatologischen Malignomen. Oncolytics Biotech Inc. hat eine Entwicklungsvereinbarung mit Merck KGaA und Pfizer Inc. zur gemeinsamen Entwicklung von Pelareorep in Kombination mit Paclitaxel und Avelumab, einem humanen Anti-PD-L1-Antikörper für die Behandlung von Hormonrezeptor-positivem/humanem epidermalem Wachstumsfaktor 2-negativem metastasierendem Brustkrebs; und PrECOG LLC. Das Unternehmen wurde 1998 gegründet und hat seinen Hauptsitz in Calgary, Kanada.
Name | Oncolytics Biotech |
CEO | Wayne F. Pisano |
Sitz | Calgary, ab Kanada |
Website | |
Industrie | Chemikalien |
Börsengang | |
Mitarbeiter | 28 |
Ticker Symbole
Börse | Symbol |
---|---|
Toronto Stock Exchange | ONC.TO |
NASDAQ | ONCY |
Frankfurt | ONYN.F |
Assets entdecken
Shareholder von Oncolytics Biotech investieren auch in folgende Assets